Abstract
The pharmaceutical industry is one of the fastest growing sectors in Indian
economy. Visiongain predicts that market for pharmaceuticals in India has
strong potential for increased growth from 2008 right through to 2023. The
industry' s leading Indian Pharma report contains unique market-based research,
including detailed interviews with key opinion leaders based in India and
abroad. Importantly, the report forecasts the overall Indian pharmaceutical
market from 2008 to 2023, as well as that of many important market segments.
Other key metrics are also included throughout the report. This is your
opportunity to gain critical insight into the potential and inner workings of
one of the world' s most important healthcare markets from the present onwards.
This new visiongain report describes India' s domestic as well as export market
for pharmaceuticals. India has had a strong domestic pharmaceutical industry
and a rapidly expanding market with a population of over a billion and a
rapidly expanding economy. Prevalence values of many diseases are likely to
increase with expansion of population, urbanisation and with higher
identification rates in the coming decade. India' s pharmaceutical market is
increasingly important in global pharma, with both domestic and foreign
companies benefiting. Healthcare provision - both public and private - is
improving, leading to fast-expanding markets for healthcare products,
especially modern pharmaceuticals, visiongain concludes.
Outsourcing for Contract Research and Manufacturing Services from India
The report also analyses India' s role in pharma outsourcing services. India is
emerging as a competitive outsourcing hub and is playing a major role in the
global pharmaceutical industry in manufacturing Active Pharmaceutical
Ingredients (APIs) and intermediates for drug makers. Global pharmaceutical
companies are establishing long-term relationships with Indian manufacturing
companies and contract research providers in India.
Generic drugs produced in India are increasingly being accepted worldwide,
with leading companies such as Ranbaxy, Cipla and Dr. Reddy' s paving the way
for others. Indian companies have increasingly taken on outsourced
manufacturing for foreign clients, in addition to marketing pharmaceuticals
themselves. There are also new drug development programmes by Indian
companies, with eventual international market launches. Outsourcing to India
has proven to be effective in saving costs and valuable developmental time.
The Indian pharmaceutical industry has taken an important role in global
pharma, not only as a manufacturer of generic drugs and APIs but also of new
formulations.
Increasing costs for research and development and low productivity have
compelled major pharmaceutical companies worldwide to outsource part of their
research and manufacturing activities to lower-cost, developing nations such
as India and China. India' s emphasis on research and development and new drug
discovery is growing. Furthermore, India is emerging as the preferred
destination for outsourcing clinical trials, with both high quality and lower
costs achieved there.
- With the introduction of ' product patent regime' in 2005, India is
expected to receive further investment from international pharmaceutical
companies in the years ahead
- Global pharmaceutical companies are establishing long-term relationships
with Indian pharmaceutical companies and the contract manufacturing affiliates
in India, in addition to establishing manufacturing, R&D and marketing bases
there
Why You Should Buy This Report
In this report you will receive the following essential information for
understanding the Indian pharma market and industry:
- The value of the Indian pharmaceutical market and its principal market
segments from 2008 to 2023
- Exports values of the Indian pharmaceutical sector present and future
- Which current or future therapies that will drive the market for India' s
pharmaceutical industry from 2008 to 2023
- Market drivers and restraints, including a comprehensive SWOT analysis
- Comprehensive views of key opinion leaders on Indian pharma
- The companies involved in the market and their business strategy
- What are the forecasts for sales for each of the therapeutic areas
- What is the present state of disease prevalence and future trends there
- What contract research and manufacturing opportunities exist for ' new
comers'
This Report is essential reading for the Following Professionals, Amongst
Others:
- Investors in the India' s pharmaceutical industry
- Business managers of multinational companies
- Business managers of India' s domestic companies
- Business managers of pharmaceutical industry related to outsourcing
- Researchers, analysts and academics interested in India' s pharmaceutical
industry
- Senior staff in healthcare authorities relevant to India
Unique Benefits When You Order This Report:
- - Original primary research and analyses. You will not find this
information anywhere else
- - Full searchable report when you buy the company or corporate editions
- - Copies can be printed off for offline reading
- - Packed with charts, analysis, figures, graphs and tables
Great Potential for the Indian Pharma Sector and Market from Present Onwards,
Visiongain Concludes
Currently, India' s largest selling medicines are anti-infective agents, but
the fast growing areas are the lifestyle-related diseases, the foreign
multinational companies will benefit from selling innovative treatments for
these conditions.
With increasing prevalence of diseases of aging and lifestyle-related diseases
associated with greater affluence, India' s pharmaceutical market will continue
to increase steadily in sales value from 2008 onwards. Furthermore, with rapid
increase in drug resistance for anti-infective agents like anti-TB,
anti-malarial and other antibiotics, visiongain further emphasises that there
will be a particularly strong market for most types of pharmaceutical agents -
both new and established - from 2008 to 2023.
View Cart
